ADM03820
Phase 1- Indications
- COVID-19
Company intelligence / Profile preview
Ology Bioservices operated as an integrated biopharmaceutical CDMO with expertise in cGMP manufacturing of biologics and medical devices. It supported government contracts for advanced development/manufacturing of medical countermeasures—including COVID‑19 monoclonal antibodies—and had at least one FDA-cleared injectable biologic product ("NanoFUSE DBM" bone graft filler). The company was acquired by National Resilience ("Resilience") in April 2021.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Ology Bioservices.